Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|June 3, 2025
Cardiology Month in Review: May 2025
Author(s)Patrick Campbell
Discover key advancements and setbacks in cardiovascular medicine from May 2025, shaping the future of cardiometabolic care and treatment options.
Advertisement
Advertisement
Amid the dynamic and fast-paced landscape of cardiovascular medicine, May 2025 delivered a mix of promising advances and sobering setbacks across the pipeline, regulatory, and clinical arenas. This month in review highlights the most important developments shaping current and future care for patients with cardiometabolic disease.
Related to this article
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Advertisement
Advertisement